Literature DB >> 1651587

Human papillomavirus type 16 immortalized cervical keratinocytes contain transcripts encoding E6, E7, and E2 initiated at the P97 promoter and express high levels of E7.

M Nasseri1, J R Gage, A Lorincz, F O Wettstein.   

Abstract

Human cervical keratinocytes represent the specific host for the genital human papillomaviruses (HPV). Transfection of these cells with the DNA of a number of the oncogenic HPVs including type 16 was recently shown to result in their immortalization but not in malignant transformation. In this report we show that viral transcripts for E6 and E7 in these cells were as abundant as in cancer derived cell lines. However, in contrast to cancer derived cell lines, immortalized cervical keratinocytes contained RNA with the potential to encode a full-length E2 protein. In addition, the levels of the E7 oncoprotein were at least as high as in cancer derived cell lines, suggesting that E2 interruption, observed in cancer derived cell lines, is not causally related to the high level of E7 expression and, therefore, deregulation of the P97 promoter may not be a prerequisite for HPV-16 associated cancer development. Furthermore, we show that E6, E7, and E2 encoding transcripts all originate from the viral promoter, P97. Unlike in cancer derived cell lines, all transcripts terminated at the early poly(A) site.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651587     DOI: 10.1016/0042-6822(91)90829-z

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

Review 1.  Counseling the patient with potentially HPV-related newly diagnosed head and neck cancer.

Authors:  John P Finnigan; Andrew G Sikora
Journal:  Curr Oncol Rep       Date:  2014-03       Impact factor: 5.075

Review 2.  Clinical implications of human papillomavirus in head and neck cancers.

Authors:  Carole Fakhry; Maura L Gillison
Journal:  J Clin Oncol       Date:  2006-06-10       Impact factor: 44.544

3.  Characterization of the methylation patterns in human papillomavirus type 16 viral DNA in head and neck cancers.

Authors:  Il-Seok Park; Xiaofei Chang; Myriam Loyo; Gaosong Wu; Alice Chuang; Myoung Sook Kim; Young Kwang Chae; Sofia Lyford-Pike; William H Westra; John R Saunders; David Sidransky; Sara Isabel Pai
Journal:  Cancer Prev Res (Phila)       Date:  2011-02

4.  Multiple changes in oncogenes and tumor suppressor genes in human retinoblastoma.

Authors:  R O Howard
Journal:  Trans Am Ophthalmol Soc       Date:  1996

5.  E2 represses the late gene promoter of human papillomavirus type 8 at high concentrations by interfering with cellular factors.

Authors:  F Stubenrauch; I M Leigh; H Pfister
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

Review 6.  Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.

Authors:  Balasubramanyam Karanam; Subhashini Jagu; Warner K Huh; Richard B S Roden
Journal:  Immunol Cell Biol       Date:  2009 May-Jun       Impact factor: 5.126

7.  Low-affinity E2-binding site mediates downmodulation of E2 transactivation of the human papillomavirus type 8 late promoter.

Authors:  F Stubenrauch; H Pfister
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

8.  Papillomavirus E7 protein binding to the retinoblastoma protein is not required for viral induction of warts.

Authors:  D Defeo-Jones; G A Vuocolo; K M Haskell; M G Hanobik; D M Kiefer; E M McAvoy; M Ivey-Hoyle; J L Brandsma; A Oliff; R E Jones
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

9.  Human papillomavirus type 11 E2 proteins repress the homologous E6 promoter by interfering with the binding of host transcription factors to adjacent elements.

Authors:  G Dong; T R Broker; L T Chow
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

10.  Identification of three transforming proteins encoded by cottontail rabbit papillomavirus.

Authors:  C Meyers; J Harry; Y L Lin; F O Wettstein
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.